ArticleCureus2026
From Cholinergic Crisis to Anticholinergic Delirium: When the Antidote Mimics the Poison.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organophosphorus pesticide poisoning remains a major public health concern due to widespread agricultural use and easy availability of these compounds. Atropine is the cornerstone of treatment for life-threatening muscarinic manifestations. However, repeated or prolonged administration can cause central anticholinergic toxicity, which may closely resemble the neurological effects of organophosphorus poisoning and delay the correct diagnosis. We report a 26-year-old woman who developed severe cholinergic toxicity after intentionally ingesting monocrotophos and was treated with mechanical ventilation, pralidoxime, and atropine. After 48 hours of atropine therapy, she developed acute agitation, hallucinations, disorientation, and peripheral anticholinergic findings despite resolution of her initial cholinergic symptoms. Other metabolic, infectious, and toxicological causes were not identified. Her symptoms resolved after atropine was discontinued, without cholinergic rebound. This case emphasizes the importance of distinguishing atropine-induced delirium from ongoing organophosphorus central nervous system (CNS) toxicity. Regular clinical reassessment and symptom-guided atropine titration may prevent unnecessary investigations, inappropriate treatment, and avoidable anticholinergic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.